Is REVELATION BIOSCIENCES, INC. (REVB) Halal?

NASDAQ Healthcare United States $4M
✗ NOT HALAL
Confidence: 67/100
REVELATION BIOSCIENCES, INC. (REVB) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.0% is acceptable, the cash and interest-bearing securities ratio of 192.1% exceeds the 30% threshold. REVELATION BIOSCIENCES, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
192.1%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 0.0%
/ 33%
192.1%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 0.0%
/ 33%
98.1%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
192.1%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 0.0%
/ 33%
98.1%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-23.95
P/B Ratio
0.2
EV/EBITDA
0.6
EV: -$6M
Revenue
$0
Beta
-0.1
Low volatility
Current Ratio
5.4

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -131.4%
Return on Assets (ROA) -62.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$8M
Free Cash Flow-$8M
Total Debt$746,784
Debt-to-Equity8.4
Current Ratio5.4
Total Assets$12M

Price & Trading

Last Close$1.13
50-Day MA$1.67
200-Day MA$5.71
Avg Volume676K
Beta-0.1
52-Week Range
$1.11
$44.77

About REVELATION BIOSCIENCES, INC. (REVB)

CEO
Mr. James M. Rolke
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$4M
Currency
USD

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is REVELATION BIOSCIENCES, INC. (REVB) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), REVELATION BIOSCIENCES, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is REVELATION BIOSCIENCES, INC.'s debt ratio?

REVELATION BIOSCIENCES, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are REVELATION BIOSCIENCES, INC.'s key financial metrics?

REVELATION BIOSCIENCES, INC. has a market capitalization of $4M. Return on equity stands at -131.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.